Overview
- On July 9, JPMorgan raised its 12‑month price target for Eli Lilly to $1,400 and RBC lifted its target to $1,500, with both firms citing stronger-than-expected demand for Mounjaro and Zepbound.
- Medicare’s July 1 GLP‑1 Bridge made Zepbound and the oral pill Foundayo available to eligible beneficiaries for about $50 a month, a change analysts say could add millions of potential patients.
- Lilly reported Q1 revenue of $19.8 billion with roughly $12.8 billion coming from Mounjaro and Zepbound, and the company raised its full‑year 2026 revenue guidance to $82–$85 billion.
- Analysts project continued Q2 strength — JPMorgan estimates about $20.7 billion in sales — but note that Lilly’s near $1.16 trillion market value and high price‑to‑earnings ratio make the stock sensitive to pricing pressure and the August 5 results.
- Investors point to Lilly’s pipeline, including oral GLP‑1 Foundayo and the triple‑agonist retatrutide, as the basis for a combined addressable market that some analysts value at more than $200 billion.